• “Description of patients excluded for Mohs surgery after pre-surgical evaluation: data from the Regesmohs Spanish registry”
Ruiz-Salas V, Garcés JR, Alonso-Alonso T, Rodríguez-Prieto MA, Toll-Abelló A, Eusebio Murillo E, et al. Actas Dermosifiliogr. 2018 May;109(4):346-350
The Spanish registry of Mohs surgery (REGESMOHS) began in July 2013, where 24 hospitals participated, and in which Sant Pau Hospital and the Teknon Medical Center played an active role. Their main objective is to describe the Mohs surgery in Spain and the factors that influence its results.
In this second article related to the Spanish registry of Mohs surgery, the objective was describe the reasons why Mohs surgery was rejected in some patients at the time of the pre surgical evaluation.
It was observed that the presence of important diseases (or comorbidities) and the deterioration of the patient health status were the main reasons for contraindicating this type of surgery.
You can have access to the full article by clicking on the following link:
• “Double myocutaneous-mucosal island flap reconstruction for defects at the base of the philtrum affecting the upper lip vermilion”.
Garcés JR, Ruiz-Salas V, Alegre Fernández M, Puig Sanz L. Dermatol Surg. 2016 May;42:677-80.
In this article, we describe the usefulness of a type of reconstructive technique called “double island flap”, to reconstruct médium defects located on the upper lip “philtrum”.
By clicking on the below link you will be able to know more details:
• “Description of Patients Undergoing Mohs surgery in Spain: Initial Report on Data from the Spanish Registry of Mohs surgery (REGESMOHS)”
Ruiz-Salas V, Garcés JR, Miñano Medrano R, Alonso-Alonso T, Rodríguez-Prieto MÁ, López-Estebaranz JL,et al Actas Dermosifiliogr. 2015;106:562-568.
El Spanish registry of Mohs surgery (REGESMOHS) began in July 2013, where 24 hospitals participated, and in which Sant Pau Hospital and the Teknon Medical Center played an active role. Their main objective is to describe the Mohs surgery in Spain and the factors that influence its results.
In this first article, the objective was to describe the characteristics of patients and cutaneous tumors treated by Mohs surgery in Spain.
Click on the following link to access the complete document:
• “Vismodegib: a review”
Ruiz Salas V, Alegre M, López-Ferrer A, Garcés JR. Actas Dermosifiliogr. 2014 ;105:744-51.
This is a review about the use of a drug called vismodegib in the treatment of advanced cases of basal cell carcinoma.
To read the complete article, I invite you to access from the following link:
• “Locally advanced and metastátic basal cell carcinoma: molecular pathways, treatment options and new targeted therapies”.
Ruiz Salas V, Alegre M, Garcés JR, Puig L. Expert Review Anticancer Ther. 2014 ;14:741-9.
This review tried to proportionate data information on molecular pathways involved in the development of basal cell carcinoma, the therapeutic options available for the treatment of those advanced and metastatic tumors, as well as new targeted therapies in development such as vismodegib.
Click on the following link to know more: